… Ruffatti and S. Iliceto participated in the planning, data collection, data analysis and
writing of the manuscript. C. … Ruffatti A., Tonello M., Cavazzana A., Bagatella P., Pengo V. …

Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …

Persistent antiphospholipid (aPL) antibodies are occasionally found in subjects without prior
history of thromboembolic events (TEs), raising the dilemma of whether to initiate or not a …

Background: Diagnosis of the antiphospholipid syndrome (APS) is difficult as a result of limited
specificity of existing assays for detecting clinically relevant antiphospholipid antibodies. …

Objective. To identify the risk factors associated with pregnancy failure in patients with APS
treated with conventional therapy. Methods. A multicentre, case–control study was conducted …

Objective Congenital heart block (CHB) is presumed to be caused by transplacental passage
of maternal immunoglobulin against Ro and La ribonucleoproteins. The recurrence rate in …

Objectives To assess risk factors for a first thrombotic event in confirmed antiphospholipid (aPL)
antibody carriers and to evaluate the efficacy of prophylactic treatments. Methods …

Background Antiphospholipid syndrome is an autoimmune, hypercoagulable state that is
caused by antiphospholipid antibodies. Anticardiolipin antibodies, anti-β2 glycoprotein-I, and …

In women diagnosed as having category I primary obstetric antiphospholipid syndrome,
clinical characteristics and the risk of subsequent thromboembolic events and further …

We performed a meta-analysis to determine whether aspirin has a significant protective
effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL +). …